Korean vaccine developer Eubiologics seeks phase 3 trials in Philippines, commits 40M doses

Korean vaccine developer, Eubiologics Co. Ltd., is eyeing phase III clinical trials of its COVID-19 shots in the Philippines as it committed to provide 40 million doses to the country, Manila's embassy in Seoul said Friday.

Ambassador Maria Theresa Dizon met this week with top Eubiologics officials at the firm's vaccine plant in Chuncheon, where they also discussed the transfer technology for vaccine development and manufacturing in the Philippines.

"Eubiologics is currently finalizing its Phase II clinical trials of their EuCorVac19 COVID vaccine in the Republic of Korea and intends to conduct Phase III clinical trials in the Philippines," an embassy statement said.

The Korean Embassy in Manila said Eubiologics has already applied for application before the Department of Science and Technology.

EuBiologics Co., Ltd., according to its website, focuses on developing vaccines against global pandemic and creating bacterial vaccine pipelines against newly emerging infectious diseases and antibiotic resistance.

In her meeting with Eubiologics executives, De Vega stressed the importance of vaccine cooperation in the overall effort to effectively respond to and manage the impact of COVID-19.

Currently, the Philippines is administering COVID-19 jabs from Sinovac, Astra Zeneca, Sputnik V,  Pfizer BioNTech, Moderna, and Johnson and Johnson.

The Philippine government expects the vaccination of 70% of the country's population by February 2022.  — RSJ, GMA News